Skip to main
AXSM
AXSM logo

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics Inc. is positioned positively due to the strong momentum of its lead product, Auvelity, driven by its novel mechanism of action, rapid onset, and efficacy in treating major depressive disorder (MDD), further bolstered by anticipated improvements in payor coverage. The company's confidence regarding the upcoming sNDA submission of AXS-05 for Alzheimer's disease-associated agitation is supported by favorable pre-NDA feedback from the FDA, reflecting strong clinical trial results demonstrating statistically significant improvements across multiple studies. Additionally, the anticipated launch of SYMBRAVO, which shows rapid and sustained relief of migraine pain, complements Axsome's promising pipeline of therapies designed to address CNS disorders with currently limited treatment options.

Bears say

Axsome Therapeutics faces multiple significant risks that contribute to a negative outlook on its stock, including potential lower market access for its product AUVELITY and setbacks in clinical trials, particularly for its leading candidate AXS-05 in treatment-resistant depression and smoking cessation. Additionally, the company may struggle to secure timely approvals for its pipeline products AXS-12 and AXS-14, which could hinder growth opportunities. There is also a concern regarding lower-than-projected commercial success due to heightened competition, as well as risks associated with long-term shareholder dilution.

Axsome Therapeutics (AXSM) has been analyzed by 24 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 24 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $145.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $145.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.